“October 2012.” That is when Kevin Lobo was appointed Chief Executive Officer of Stryker, one of the world’s leading medical technology companies. He had joined the organization only the year before, in 2011, taking on the role of Group President of Orthopaedics. It was enough time to see the company clearly, to understand where its strengths lived and where its potential was still waiting to be unlocked.
When the CEO appointment came, Kevin was ready. Then, in July 2014, he became Chair of the Board as well, assuming the full weight of Stryker’s direction at both the executive and governance levels. “That combination of roles, held simultaneously with intention and consistency, has defined the shape of his leadership ever since.”
More Than Sixty Acquisitions and What They Actually Mean
There is a number attached to Kevin’s tenure at Stryker that deserves to be examined carefully, not celebrated automatically, but examined.
More than 60 acquisitions. In the context of medical technology, acquisitions are not simply financial transactions. They are decisions about which innovations to bring inside the tent, which capabilities to add to the organization’s arsenal, and which directions the company believes the future of healthcare is moving in. Each acquisition represents a judgment call, made under conditions of uncertainty, about what the next chapter of medicine will require.
More than sixty of those judgment calls, made over the course of Kevin’s leadership, have collectively advanced Stryker’s innovation and global market presence in ways that no single internal initiative could have achieved alone.
That is not a passive record. That is an aggressive, sustained, and deliberate strategy of building a company that can meet the world’s healthcare needs at scale.
“And behind every one of those sixty-plus decisions is a leader who did the analytical work before signing anything.”
A Career Built in Layers
To understand how Kevin leads Stryker, it helps to understand how long and in how many different rooms he built the skills to do so.
Before Stryker, there was Johnson & Johnson, where he held some of the most demanding roles in medical technology leadership. He served as President of Ethicon Endo Surgery, as President of J&J Medical Products Canada, and in CFO roles within J&J’s consumer and women’s health divisions. These were not interchangeable titles. Each one required a distinct kind of expertise, a different way of thinking about products, markets, customers, and accountability.
Before J&J, Kevin held finance and management roles at Rhone-Poulenc, including assignments in Europe, broadening his perspective into international markets at a point in his career when many executives are still consolidating their domestic footing.
And before that, there were formative years at Kraft Canada, Unilever, and KPMG, each institution adding a different layer to a professional foundation that would, eventually, prove exceptionally well-suited to leading one of the world’s most complex healthcare companies.
This is not a career that arrived at Stryker by accident. It is a career that assembled, piece by careful piece, exactly the range of experience that the job demands.
The Credentials Behind the Vision
Kevin holds a Bachelor of Commerce from McGill University, an MBA from the University of Toronto, and is a Chartered Accountant.
In a field where the most visible credentials are often clinical or scientific, Kevin’s are financial and commercial. And yet, his record at Stryker has demonstrated, conclusively, that financial rigor and bold innovation are not competing instincts. They are complementary ones.
“A Chartered Accountant who has overseen more than sixty acquisitions and been named to Forbes’ list of America’s Most Innovative Leaders is, by any definition, someone who has found a way to make the numbers and the vision speak the same language.”
That is not a small achievement. In the history of medical technology leadership, it is a genuinely distinctive one.
The Recognition That Tells the Real Story
Recognition in business is easy to dismiss as a vanity exercise. But the particular constellation of honors that Kevin has accumulated over his tenure at Stryker tells a story that is worth taking seriously.
He has been named to Forbes’ list of America’s Most Innovative Leaders. He received the Ellis Island Medal of Honor in 2023, one of the most meaningful civic distinctions available to leaders in American public life, awarded to those who have made extraordinary contributions to their communities and their country. And he was honored with a CEO for All Leadership Award from Great Place to Work, recognizing leadership that does not just perform excellence but creates the conditions for it across an entire organization.
These are not all the same kind of recognition. One speaks to innovation. One speaks to civic contribution. One speaks to the experience of the people working inside the organization he leads. Together, they sketch a portrait of a leader operating across multiple dimensions at once.
The Culture That Kevin Built
Perhaps the most telling part of Kevin’s legacy at Stryker is not any specific acquisition or market expansion. It is the culture. During his tenure, Stryker has earned consistent, sustained recognition as a Great Place to Work globally, across multiple categories, including the World’s Best Workplaces and the 100 Best Companies to Work For.
Those designations are not given to companies where leadership treats culture as a side project. They are given to companies where the people at the top have made a genuine and ongoing commitment to the experience of every person in the organization.
In an industry that can easily become consumed by the complexity of its own science and regulation, Kevin has kept the human element central. Not as a branding exercise. As a leadership conviction.
That conviction, expressed year after year and reflected in what ‘great place to work’ recognition requires, is one of the most underappreciated dimensions of his impact.
Where He Shows Up Beyond Stryker
Kevin’s sense of accountability extends well beyond the walls of his own organization. He serves on the board of Parker Hannifin (NYSE: PH) and the Advanced Medical Technology Association (AdvaMed), one of the industry’s most important advocacy bodies. He is a member of the Business Council, and he serves as Chair of the Valley Health System’s board of trustees in New Jersey.
Each of these commitments represents time, judgment, and responsibility extended into an institution other than the one that employs him. That is a mark of a leader who understands that their work does not begin and end with their own organization. That the health of an industry, and the health of a community, are things that require active stewardship from those with the standing and the skill to provide it.
Kevin has that standing. And he uses it.
A Force in 2026 and Beyond
Stryker in 2026 is a company defined by scale, by innovation, by a culture that has been recognized repeatedly and globally, and by more than sixty strategic moves that have each added something meaningful to its ability to serve patients and partners worldwide.
At the center of all of that is Kevin Lobo: Chartered Accountant, Forbes honoree, Ellis Island Medal recipient, and a leader who joined a company in 2011 and spent the years that followed building it, carefully and ambitiously, into something the world’s healthcare system genuinely depends on.
“That is what more than a decade of focused, principled, people-centered leadership looks like from the outside.” From the inside, it probably just looks like showing up every single day and doing the work.
Quotes
“Stryker’s strong emphasis on people and culture has earned it steady recognition as a Great Place to Work globally.”
“Under his leadership, Stryker has completed more than 60 acquisitions and advanced innovation and global market presence.”
